Jacobs Levy Equity Management
MLNT

Jacobs Levy Equity Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Jacobs Levy Equity Management’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,440
Closed -$173K – 1113
2018
Q2 		$173K Buy
+5,440
New +$196K ﹤0.01% 965

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jacobs Levy Equity Management's MLNT Position: Q3 2018 in Review

Jacobs Levy Equity Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2018, closing a stake of 5,440 shares — an estimated $173K sold.

Jacobs Levy Equity Management first reported a position in MLNT in Q2 2018 and held it in 1 quarter. The position peaked at $173K in Q2 2018. 91 funds tracked by Wall St. Rank hold MLNT as of Q3 2018.

  • Jacobs Levy Equity Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 5,440 Melinta Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $173K.
  • Jacobs Levy Equity Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Melinta Therapeutics, Inc. Common Stock position peaked at $173K in Q2 2018.
  • 91 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.